PR
Therapeutic Areas
HCW Biologics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| HCW9206 | Reagent for CAR-T/NK Cell Manufacturing (Cancer, Infectious Diseases) | Commercial-Ready |
| HCW9201 | Reagent for Immunotherapeutic Production | Commercial-Ready |
| HCW11-006 | Not Specified (In Vivo Applications) | Not Disclosed |
| TOBI-based molecule | Solid Tumors (Ovarian, Pancreatic Cancer) | Phase 1/2 |
| Fusion Immunotherapeutic | Autoimmune Disease | Clinical Trial |
Leadership Team at HCW Biologics
HC
Hing C. Wong
Founder, Chief Executive Officer
RB
Rebecca Byam
Chief Financial Officer
LF
Lee Flowers
Senior Vice President Business Development
JE
Jack Egan
Vice President of Manufacturing and Development
NV
Nicole Valdivieso
Vice President Legal Affairs
ST
Scott T. Garrett
Board of Directors
RS
Rick S. Greene
Board of Directors
LM
Lisa M. Giles
Board of Directors